Trial Profile
A phase II trial of KX2-391 in patients with ovarian cancer.
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2012
Price :
$35
*
At a glance
- Drugs Tirbanibulin (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Athenex
- 05 Dec 2012 Status changed from planning to unconfirmed.
- 26 Apr 2011 New trial record